Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL.

Anticancer Res. 2011 Apr;31(4):1417-20.

PMID:
21508395
2.

Appraising iniparib, the PARP inhibitor that never was--what must we learn?

Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.

Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15. Review.

PMID:
24129347
3.

Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.

Endocr Relat Cancer. 2016 Oct;23(10):T57-67. doi: 10.1530/ERC-16-0269. Epub 2016 Aug 10. Review.

4.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
5.
6.

The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.

Drew Y, Plummer R.

Curr Opin Obstet Gynecol. 2010 Feb;22(1):67-71. doi: 10.1097/GCO.0b013e328334ff57. Review.

PMID:
19934756
7.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17. Review.

PMID:
25341009
8.

PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

Peralta-Leal A, Rodríguez-Vargas JM, Aguilar-Quesada R, Rodríguez MI, Linares JL, de Almodóvar MR, Oliver FJ.

Free Radic Biol Med. 2009 Jul 1;47(1):13-26. doi: 10.1016/j.freeradbiomed.2009.04.008. Epub 2009 Apr 10. Review.

PMID:
19362586
9.

Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.

Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53. Review.

PMID:
20645701
10.

An update on PARP inhibitors--moving to the adjuvant setting.

Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M.

Nat Rev Clin Oncol. 2015 Jan;12(1):27-41. doi: 10.1038/nrclinonc.2014.163. Epub 2014 Oct 7. Review.

PMID:
25286972
11.

BRCA and pancreatic cancer.

Brennan GT, Relias V, Saif MW.

JOP. 2013 Jul 10;14(4):325-8. doi: 10.6092/1590-8577/1652. Review.

12.

The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.

Chionh F, Mitchell G, Lindeman GJ, Friedlander M, Scott CL.

Asia Pac J Clin Oncol. 2011 Sep;7(3):197-211. doi: 10.1111/j.1743-7563.2011.01430.x. Review.

PMID:
21884432
13.

BRCA-associated pancreatic cancer: the evolving management.

Leung K, Saif MW.

JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462. Review.

14.

BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.

Pothuri B.

Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307. Review.

PMID:
24131965
15.

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Plummer R.

Breast Cancer Res. 2011 Aug 16;13(4):218. doi: 10.1186/bcr2877. Review.

16.

Pancreatic cancer: BRCA mutation and personalized treatment.

Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X.

Expert Rev Anticancer Ther. 2015;15(10):1223-31. doi: 10.1586/14737140.2015.1086271. Epub 2015 Sep 7. Review.

PMID:
26402249
17.

PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.

Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H.

Acta Clin Belg. 2011 Jan-Feb;66(1):2-9. Review.

PMID:
21485757
18.

The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.

Martinez-Useros J, Garcia-Foncillas J.

Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18. Review.

19.

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.

Zhang J.

Asian J Androl. 2014 May-Jun;16(3):401-6. doi: 10.4103/1008-682X.123684. Review.

20.

[PARP inhibitors and breast cancer: update and perspectives].

Gonçalves A.

Bull Cancer. 2012 Apr 1;99(4):441-51. doi: 10.1684/bdc.2012.1553. Review. French.

Supplemental Content

Support Center